MARKET

ARPO

ARPO

Aerpio Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5600
-0.0300
-5.08%
Closed 16:00 12/06 EST
OPEN
0.5900
PREV CLOSE
0.5900
HIGH
0.6010
LOW
0.5500
VOLUME
168.90K
TURNOVER
--
52 WEEK HIGH
4.250
52 WEEK LOW
0.4500
MARKET CAP
22.73M
P/E (TTM)
-0.8317
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARPO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARPO News

  • Here's Why We're A Bit Worried About Aerpio Pharmaceuticals's (NASDAQ:ARPO) Cash Burn Situation
  • Simply Wall St..11/11 11:59
  • Aerpio Pharms EPS in-line
  • seekingalpha.11/07 17:29
  • Aerpio Pharmaceuticals Q3 EPS $(0.11) Beats $(0.12) Estimate
  • Benzinga.11/07 13:27
  • Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update
  • Business Wire.11/07 12:00

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.32%

Hot Stocks

Name
Price
%Change

About ARPO

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
More

Webull offers Aerpio Pharmaceuticals Inc (ARPO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.